A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical
study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced,
metastatic or recurrent non-squamous non-small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Institute Of Biological Products
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences